Form 4: Danimer Scientific Executive Granted Stock Appreciation Rights and Performance Stock Award

Phillip D. Van Trump, Chief Technology Officer of Danimer Scientific, received stock appreciation rights and a performance stock award on April 3, 2024, under the company's 2020 Long-Term Incentive Plan.

Summary

• On April 3, 2024, Phillip D. Van Trump, the Chief Technology Officer of Danimer Scientific, received stock appreciation rights (SARs) for 263,410 shares and a performance stock award (PSA) for 151,585 shares under the company's 2020 Long-Term Incentive Plan.
• The SARs have an exercise price of $1.06 and will vest in three tranches: 87,803 shares on each of April 3, 2025, and April 3, 2026, and 87,804 shares on April 3, 2027, expiring on April 3, 2034.
• The PSA's vesting is contingent upon achieving specific Total PHA Revenue and Adjusted EBITDA targets by December 31, 2026, as measured by the company's audited consolidated financial statements.
• 50% of the PSA (Total PHA Revenue Metric Shares) will vest based on Total PHA Revenue: 50% vesting at $135 million and 100% vesting at $157 million, with pro-rata vesting in between.
• The other 50% of the PSA (Adjusted EBITDA Metric Shares) will vest based on Adjusted EBITDA: 50% vesting at $17.2 million and 100% vesting at $22.3 million, with pro-rata vesting in between.
• The PSA will vest no later than April 3, 2027, or the Reporting Person's Termination Date.

Sentiment

Score: 7

Explanation: The document is neutral to slightly positive. It details standard executive compensation practices with performance-based incentives, suggesting confidence in future growth.

Positives

• The grants of SARs and PSAs align the executive's interests with the company's long-term performance.
• The performance-based vesting of the PSA incentivizes the achievement of specific financial targets (Total PHA Revenue and Adjusted EBITDA).

Risks

• The vesting of the PSA is dependent on the company achieving specific financial targets, which may not be met.
• The value of the SARs is dependent on the company's stock price, which is subject to market fluctuations.

Future Outlook

The vesting of the performance stock award is contingent upon the company achieving specific Total PHA Revenue and Adjusted EBITDA targets by the end of 2026.

Industry Context

This type of equity compensation is common in the industry to incentivize executives and align their interests with those of shareholders. The performance-based vesting adds an extra layer of motivation to achieve specific financial goals.

Comparison to Industry Standards

• Performance-based equity awards are a common practice among publicly traded companies, particularly in growth-oriented sectors like biotechnology and sustainable materials.
• Companies like Amyris and Corbion also utilize performance-based metrics in their executive compensation packages, often tied to revenue growth, EBITDA, or specific project milestones.
• The specific targets for Total PHA Revenue and Adjusted EBITDA would need to be compared to Danimer's historical performance and industry benchmarks to assess their difficulty and reasonableness.

Stakeholder Impact

• Shareholders: The equity grants align executive interests with shareholder value creation.
• Employees: The performance-based vesting may motivate employees to achieve company goals.
• Executive: The executive is incentivized to drive revenue and profitability.

Key Dates

Keywords

Danimer Scientific, Stock Appreciation Rights, Performance Stock Award, Executive Compensation, PHA Revenue, Adjusted EBITDA, Vesting, DNMR